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Description of evidence collection method
A literature review of the scientifi c articles referenced in 
these guidelines was conducted with the MEDLINE data-
base. The evidence search was based on real clinical sce-
narios, and the following keywords (MeSH terms) were used: 
Arthritis, Rheumatoid, Therapy (early OR late OR later OR 
time factors OR delay), Prognosis, Remission, Steroids, Anti-
Infl ammatory Agents, Non-Steroidal, NSAIDs, Diclofenac, 
Ibuprofen, Indomethacin, Piroxicam, COX-2, Celecoxib, Etori-
coxib, Disease-modifying antirheumatic drug OR DMARD, 
Methotrexate, Gold sodium, Lefl unomide, Sulfasalazine, 
Hydroxychloroquine, Tumor Necrosis Factor-alpha, Adali-
mumab, Certolizumab, Etanercept, Infl iximab, Golimumab, 
Rituximab, Tocilizumab and Abatacept.
Grade of recommendation and strength of evidence
A: Most consistent experimental and observational 
studies.
B: Less consistent experimental and observational studies.
C: Case reports (uncontrolled studies).
D: Opinion that is not substantiated by critical evaluation, 
based on consensus, physiological studies or animal 
models.
Objective
These guidelines aim to provide recommendations for the 
treatment of rheumatoid arthritis in Brazil. Although North 
American and European guidelines for the treatment of rheu-
matoid arthritis have been recently published, it is important 
to review the subject with regard to specifi c aspects of Brazil-
ian reality. Thus, the ultimate purpose of the establishment of 
consensus guidelines for the treatment of rheumatoid arthritis 
in Brazil is to provide an orientation and foundation for Brazil-
ian rheumatologists with evidence from scientifi c studies and 
the experience of a committee of experts on the subject. Thus, 
therapeutic approaches to rheumatoid arthritis within the Bra-
zilian socioeconomic context will be standardized, while phy-
sician autonomy will be maintained with regard to the indica-
tion/selection of available treatment options.
As knowledge in this scientifi c fi eld progresses rapidly, we 
suggest biannual updates to these guidelines.
Introduction
Rheumatoid arthritis (RA) is a systemic and infl ammatory au-
toimmune disease that is characterized by the preferential im-
pairment of the synovial membranes of peripheral joints. The 
RA prevalence varies between 0.5% and 1% of the population, 
and RA affects predominantly women and adults in the 30- to 
50-year age group1,2(B).
The generally symmetrical involvement of small and large 
joints is the main feature of RA, and involvement of the hands 
and feet is common. The chronic and destructive nature of the 
disease can lead to signifi cant functional limitations, including 
the loss of ability to work and an impaired quality of life, unless 
a diagnosis is made at an early stage of the disease and treat-
ment leads to clinical improvements3(B). In addition to the ir-
reversible deformity and functional limitations, patients with 
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advanced-stage RA might have lower survival rates, a fi nding 
that highlights the severity of this disease4(B) 5(D).
RA-related costs are high as the result of both direct (spend-
ing on various medications, such as expensive biologic drugs, 
and medical and hospital expenses) and indirect (loss of per-
sonal productivity, absenteeism, payment of disability pen-
sions and a total loss of working capacity) factors6(B).
In the last two decades, there have been signifi cant ad-
vances in an understanding of RA physiopathology, accom-
panied by the development of new therapeutic categories and 
the implementation of different treatment strategies, patient 
monitoring and intensive intervention and disease control at 
early symptomatic stages7(D). The initial period of the disease, 
particularly the fi rst 12 months, is known as early RA5(D) and is 
considered to be a window of therapeutic opportunity, a time 
during which rapid and effective pharmaceutical intervention 
can change the long-term disease course. These interventions 
result in better disease control and the possibility of sustained 
RA remission7,8(D).
Treatment of RA
RA treatment includes patient and family education, drug ther-
apy, physiotherapy, psychosocial support, occupational therapy 
and surgical approaches. Drug therapies that will be addressed 
in this document include non-steroidal anti-infl ammatory 
drugs (NSAIDs), corticosteroids, biologic and synthetic disease-
modifying anti-rheumatic drugs (DMARDs) and immunosup-
pressive drugs.
DMARDs should be indicated for all patients once a diag-
nosis of RA9(B) has been established. The use of DMARDs can 
be considered for patients with undifferentiated arthritis and 
positive test levels for RA predictive biomarkers such as anti-
cyclic citrullinated peptides (anti-CCPs) and/or rheumatoid fac-
tors (RFs)10(B).
Table 111-44(A) 45-64(B) 65-80(D) summarizes the DMARDs that are 
most frequently used in Brazil along with their presentations, 
doses and monitoring considerations.
1. Is disease treatment with the intent to achieve 
remission a feasible goal?
Once a diagnosis of RA has been established, an initial disease 
assessment is important and should include the adequate 
monitoring of disease activity by assessing not only articular 
but also extra-articular manifestations and the presence of co-
morbidities.
Some of the parameters that have been found to correlate 
with RA activity include patient visual pain scales, patient and 
physician-reported disease activity, the number of tender and 
swollen joints, instruments for functional capacity assess-
ments (e.g., the Health Assessment Questionnaire – HAQ), in-
fl ammatory markers (e.g., erythrocyte sedimentation rate – ESR 
and/or C-reactive protein – CRP), fatigue, duration of morning 
stiffness, radiography of the hands, wrists and feet and qual-
ity of life indices (e.g., the Short Form – SF-36)81-83(A) 84(B) 85,86(C).
Composite indices of disease activity (CIDAs) have been cre-
ated and validated with these parameters. The main indices 
are the one based on 28 joint count (Disease Activity Score 28 
– DAS-28), the simplifi ed disease activity index (SDAI) and the 
clinical disease activity index (CDAI). These indices use a more 
simplifi ed count of 28 joints (bilateral proximal interphalan-
geal, metacarpophalangeal (MCP), wrist, elbow, shoulder and 
knee joints) and determine a numerical value for RA activity. 
Tables 2, 3 and 4 detail the calculations and uses for these in-
dices87-95(A) 96(B).
There are good correlations between the CIDAs (CDAI, SDAI 
and DAS-28), and any of these indices can be used alone. Pa-
tients who are in remission or have low disease activity accord-
ing to any index also have reduced radiographic progression 
and improved functional outcomes. Therefore, the aim should 
always be to keep the patient in clinical remission or, if this 
outcome is not possible, in a state of low disease activity87(A).
The use of methotrexate (MTX), especially in combina-
tion with other DMARDs (gold, chloroquine or sulfasalazine), 
led to clinical remission in 14.0%97(B), 33.3%98(A), 38.0%3(B) and 
95%99(A) of adult patients with active RA of a duration ranging 
between four months and fi ve years (mostly between one and 
two years), according to the American College of Rheumatol-
ogy (ACR) criteria. The best results were observed in the fi rst 6 
months after treatment. According to DAS-28 criteria, the re-
mission rate at 24 months is 76%100(B).
A combination of MTX and infl iximab led to remission in 
70% (ACR criteria)101(A) and 21.3% (SDAI criteria)102(A) of patients 
with RA of a duration less than 36 months who were evaluated 
between 54 weeks and 24 months. Similarly, MTX and etaner-
cept combinations have achieved remission rates in a period 
of 12 to 36 months in 37% (DAS-44 ≤ 1.6)103(A), 50% (DAS-28 ≤ 
2.6)43,45,104(A) and 50% (DAS-28 ≤ 3.2) of patients105(A).
Remission, as measured by the DAS-28 ≤ 2.6 parameter, was 
achieved in 43% to 45% of patients with active RA (12 months) 
within four to nine years with a combination of adalimumab 
and MTX28,106(A). The remission rate, as measured by SDAI 
criteria, was 15% at 24 months107(B). The rates of early (in the 
fi rst 12 months) remission in these patients, according to dif-
ferent criteria, were 47.7%, 50.8% and 32.3% for EULAR (Euro-
pean League against Rheumatism; DAS-28), ACR70 and DAS-28, 
respectively108(B).
Responses to recent RA treatments (less than 24 months of 
illness) with combinations of DMARDs (MTX, gold, chloroquine 
or sulfasalazine) have also been measured according to several 
criteria or parameters during remission periods ranging from 
2–11 years; the different criteria included ACR (14%–48%)109-113(B), 
DAS ≤ 2.4 (39%–43%)114,115(B) and DAS-28 ≤ 2.6 (23%–51%)116,117(B).
Recommendation
RA patient remission, as measured by any of the objective 
parameters of disease activity (DAS, DAS-28, SDAI and CDAI), 
should be considered as central objective of patient treatment.
2. Does the early initiation of RA treatment offer 
benefi ts over a later initiation with respect to 
clinical and radiographic prognosis?
In patients who began treatment with non-biologic DMARDs, 
the remission rate at 12 months, defi ned as a CDAI score < 
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Table 1 – Disease-modifying antirheumatic drugs used for treating rheumatoid arthritis in Brazil.
Drug Presentation Dose Clinical response and monitoring
Synthetic disease-modifying antirheumatic drugs
Methotrexate Tablets: 2.5 mg
Solution for injection: 
50 mg/2 mL
10–30 mg/week 
(orally, IM or SC)
Reduces signs and symptoms of disease activity, 
improves the functional status, and reduces 
the radiographic disease progression. Currently 
considered the standard drug for treating RA. 
Monitoring: blood count, creatinine and liver 
enzymes every 4–12 weeks.
Sulfasalazine Tablets: 500 mg 1–3 g/day (orally) Reduces signs and symptoms of disease activity, 
improves the functional status, and reduces the 
radiographic disease progression. Monitoring: blood 
count and liver enzymes every 8–12 weeks. Can be 
associated with MTX and other DMARDs.
Lefl unomide Tablets: 20 mg 20 mg/day or alternate days 
(orally)
Reduces signs and symptoms of disease activity, 
improves the functional status, and reduces the 
radiographic disease progression. Monitoring: 
blood count, creatinine and liver enzymes every 
4–12 weeks. Can be associated with MTX and other 
DMARDs.
Hydroxychloroquine 
sulfate
Tablets: 400 mg Up to 6 mg/kg/day (orally) Antimalarials are currently considered less potent 
drugs, and should be used at initial cases of RA 
or undifferentiated arthritis, with low erosive 
potential. Can be associated with MTX and other 
DMARDs. Monitoring: initial ophthalmologic exam 
and annually after fi ve years (or annually since 
the beginning, in the presence of risk factors for 
maculopathy or retinopathy).
Chloroquine 
disphophate
Tablets or capsules: 
150 mg or 250 mg
Up to 4 mg/kg/day (orally)
Gold salts 
(aurothioglucose 
or sodium 
aurothiomalate) 
Solution for injection: 
50 mg/0.5 mL 
50 mg/week, deeply IM, 
usually initiating with 25 
mg/week. After control, 
fortnightly and monthly 
doses. The cumulative dose 
should not exceed 3 g
Effective in controlling symptoms and reducing 
the radiographic disease progression, rarely used 
in Brazil, due to their adverse effects and low 
availability. Monitoring: monthly; blood count, liver 
enzymes, and urinalysis.
Biologic disease-modyfi ng antirheumatic drugs
Tumor necrosis 
factor blockers
Effective in controlling symptoms and reducing 
the radiographic disease progression. Should be 
preferably prescribed after failure of two schedules 
with synthetic DMARDs (one of which should 
include the combination with synthetic DMARDs, 
with MTX preferably as the anchor drug), associated 
with MTX or other synthetic DMARD. Monitoring: 
investigation of latent TB before starting treatment 
(clinical history, chest radiography, PPD and/or 
IGRA), blood count, liver enzymes every 4–12 weeks. 
Careful monitoring of the occurrence of infection, 
particularly during the fi rst year of use.
Adalimumab Prefi lled syringes: 40 mg 40 mg SC every 15 days
Certolizumab Prefi lled syringes: 200 mg 400 mg SC every two weeks, in 
weeks 0, 2 and 4, and, then, 
200 mg every two weeks, or 
400 mg every four weeks
Etanercept 25-mg and 50-mg vials or 50-
mg prefi lled syringes  
50 mg/week
Infl iximab Vials: 100 mg 3–5 mg/kg/dose  IV infusion 
in weeks 0, 2 and 6, followed 
by the same dose every 6–8 
weeks 
Golimumab Prefi lled pen: 50 mg 50 mg SC monthly
(continued on next page)
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2.8, was 21.3% in those with a disease duration of fi ve years 
or less, compared to 19.6% in patients with a disease duration 
between 6–10 years and 13.5% in those with a disease dura-
tion of at least 11 years. Therefore, there is a 1.7% (number 
needed to treat – NNT: 60) and 7.8% (NNT: 13) greater chance 
of response (remission) when synthetic non-biologic DMARD 
treatment is initiated within the fi rst fi ve years of the disease, 
compared with 6–10 years or after 11 years of the disease, 
respectively51(B).
In patients who received anti-TNF biologic DMARD treat-
ment, the benefi t of early treatment in the fi rst fi ve years of 
the disease was 4.6% (NNT: 22) or 9.5% (NNT: 10) compared 
with treatment after 6–10 years or more than 11 years, 
respectively51(B). The percentage of patients who achieved 
sustained remission remained higher in patients who were 
treated in the fi rst fi ve years of disease throughout the course 
of treatment.
In patients who were diagnosed with RA within the fi rst 
fi ve years since the onset of symptoms, the use of synthetic 
DMARDs (MTX, lefl unomide, sulfasalazine, chloroquine/hy-
droxychloroquine, intravenous (IV) gold sodium, cyclosporine) 
within the fi rst year of symptoms led to reduced radiographic 
disease progression (measured by joint damage according to 
the Ratingen score) than for patients whose treatment started 
after symptoms had occurred for one to fi ve years. Patients 
with for years of symptoms had a 0.31% greater chance of 
Table 1 – Disease-modifying antirheumatic drugs used for treating rheumatoid arthritis in Brazil. (continued)
Drug Presentation Dose Clinical response and monitoring
Biologic DMARDs
Costimulation 
modulator
Abatacept
250-mg vials IV infusion of 500 mg in 
patients weighing less than 
60 kg, of 750 mg in patients 
weighing 60-100 kg, and of 
1,000 mg in patients over 100 
kg, every four weeks
Reduces signs and symptoms of disease activity 
and the radiographic disease progression . Can be 
prescribed after failure of synthetic DMARDs or 
failure of and/or intolerance to biologic DMARDs. 
It is preferentially used in association with MTX or 
other synthetic DMARDs.
Monitoring: blood count and liver enzymes every 
4–8 weeks. Occurrence of infection should be 
monitored.
B lymphocyte 
depletion agent
Rituximab
500-mg vials 500 mg to 1 g IV on days 0 and 
14 (1–2 g/cycle)
Effective in reducing signs and symptoms of RA 
and the radiographic disease progression. Can be 
prescribed after failure of and/or intolerance to 
anti-TNF or other biologic DMARDs. It should not be 
prescribed after failure of synthetic DMARDs, except 
for exceptional situations. The presence of RF and/
or anti-CCP predicts better therapeutic response 
to rituximab. It should be preferably prescribed in 
association with MTX or other synthetic DMARD. 
The cycles can be repeated at minimum intervals of 
six months, according to disease evolution. 
Monitoring: blood count and liver enzymes every 4–12 
weeks. Occurrence of infection should be assessed.
IL-6 receptor blocker
Tocilizumab
80-mg or 200-mg vials 8 mg/kg/dose on IV infusion 
every four weeks
Effective in reducing signs and symptoms of RA 
and the radiographic disease progression. Can be 
prescribed after failure of synthetic DMARDs or 
failure of and/or intolerance to anti-TNF or other 
biologic DMARDs. Preferential use in association 
with MTX or other synthetic DMARDs, although it 
can be used as monotherapy.
Monitoring: blood count, liver enzymes, and lipid 
profi le at every infusion.
Immunosuppressive drugs Considered less effective in controlling signs and 
symptoms of RA and reducing radiographic disease 
progression. They are inferior options compared 
with DMARDs. They are mainly indicated to treat 
extra-articular manifestations and vasculitis.
Azathioprine Tablets: 50 mg 1–3 mg/kg/day, orally Monitoring: blood count and liver enzymes every 4–8 
weeks.
Cyclophosphamide Tablets: 50 mg 
200-mg or 1,000-mg vials
2–2.5 mg/kg/day, orally, or 
monthly pulse therapy with 
750 mg to 1 g/m2 of body 
surface, IV, every four weeks
Reserved for patients with severe extra-articular 
manifestations. 
Monitoring: blood count, liver enzymes, and 
urinalysis (due to the risk of hemorrhagic cystitis) 
every four weeks.
Cyclosporine Tablets: 50 and 100 mg 3–5.0 mg/kg/day, orally Blood pressure and renal function every 2–4 weeks.
RA, rheumatoid arthritis; DMARD, disease-modifying antirheumatic drug; IGRA, interferon gamma release assays; IM, intramuscular; IV, 
intravenous; MTX, methotrexate;  PPD, tuberculin skin test; RTX, rituximab; SC, subcutaneous.
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joint damage progression per year than patients who were 
treated after less than one year of symptoms118(B).
Early administration of DMARD treatment (less than nine 
months from symptom onset) produced a 33% relative reduc-
tion in radiographic disease progression during the following 
three years119(B).
It was also found that for patients whose treatment be-
gan with 3 g/day of sulfasalazine or more than 15 mg/week 
of MTX in the fi rst three months after symptom onset, the 
following results were observed in comparison to patients 
whose treatment began after 12 months: a 40% increase in 
the number of patients with responses within 32 months (as 
measured by DAS-28 < 3.2; NNT: 2); a 4-fold reduction in joint 
damage progression (measured by the Larsen radiographic 
score) and a 35% increase (NNT: 3) in the number of patients 
who achieved 50% and 70% ICR120(B).
However, in patients with symptom durations of less than 
24 months, no differences in the ACR (20 or 50) or DAS-44 < 
1.6 response rates were found between patients who began 
non-biologic DMARD therapy after less than fi ve months of 
Table 2 – Calculation and total value of composite indices of disease activity (CIDAs).
Elements SDAI CDAI DAS-28 (4 variables)
Swollen joint count (0-28) Simple sum (0-28) Simple sum Square root of the simple sum
Painful joint count (0-28) Simple sum (0-28) Simple sum Square root of the simple sum
Acute phase reactants CRP (0.1–10 mg/dL) - ESR 2-100 mm
Overall assessment of health 
(patient)
- or CRP 0.1-10 mg/dL logarithmic 
transformation
Global assessment of disease 
(patient)
(0-10 cm) (0-10 cm) 0-100 mm
Global assessment of disease 
(evaluator)
(0-10 cm) (0-10 cm) -
Total index Simple sum Simple sum -
(Change in rate) (0.1-86) (0–76) Number requires entry into the 
calculator (0.49-9.07)
SDAI, simplifi ed disease activity index; CDAI, clinical disease activity index; DAS-28, disease activity index (28 joints); CRP, C-reactive protein; 
ESR, erythrocyte sedimentation rate. Ranges of 2-100 mm/h for ESR and 0.1-10 mg/dL for CRP are assumed.
Table 3 – Cutoffs for composite indices according to RA 
activity.
Index State of disease 
activity
Cutoffs
SDAI Remission
Low
Moderate
High
≤ 5
> 5 and ≤ 20
> 20 and ≤ 40
> 40
CDAI Remission
Low
Moderate
High
≤ 2.8
≤ 10
> 10 and ≤ 22
> 22
DAS-28 Remission
Low
Moderate
High
≤≤ 2.6
> 2.6 and ≤ 3.2
> 3.2 and ≤ 5.1
> 5.1
SDAI, simplifi ed disease activity index; CDAI, clinical disease 
activity index; DAS-28, disease activity index (28 joints).
Modifi ed from Aletaha D, Smolen JS. The Simplifi ed Disease 
Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): 
A review of their usefulness and validity in rheumatoid arthritis. 
Clin Exp Rheumatol 2005; 23(39):S100–8. 
Table 4 – Responses according to variations in the 
Composite Indices of Disease Activity points.
Index Response Type
Response 
EULAR-DAS-
2887,88(A)
Good: down > 1.2 points and patients achieve 
DAS-28 with low activity (≤ 3.2).
Moderate: down 1.2 points on DAS-28; down 
between 0.6 and 1.2 points with a decline in 
disease activity from high to moderate activity 
or moderate to low activity.
SDAI response90
(A)
Good: down 17 points.
Moderate: down 7 points.
CDAI response90 
(A)
BGood: down 14 points.
Moderate: down 6 points.
SDAI, simplifi ed disease activity index; CDAI, clinical disease 
activity index, DAS-28; disease activity index (28 joints).
Modifi cation of: Aletaha D, Funovits J, Wards MM, Smolen JS, 
Kvie TK. Perception of improvement in patients with rheumatoid 
arthritis varies with disease activity levels at baseline. Arthritis 
Rheum. 2009;61:313–20.
symptoms and those who started treatment after more than 
fi ve months 121(B).
If four months after symptom onset is set as the cutoff 
for delayed or retarded treatment with 1.0 g of sulfasalazine 
(monotherapy) or 500 mg of sulfasalazine twice per day, 7.5 
mg of methotrexate per week, 300 mg of hydroxychloroquine 
and 5 mg of prednisone per day (combination therapy), the 
disease remission rate in response to earlier treatment (< 4 
months) is 24% greater (NNT: 4) in patients who underwent 
monotherapy, despite the similar time course for those who 
underwent combination therapy110(B).
In patients with early RA who were treated for two years 
with DMARDs (MTX, combined or not with adalimumab), the 
additional time to achieve remission (SDAI) in the fi rst year of 
treatment was accompanied by an increase in joint damage 
progression, as evaluated by imaging, in the second year107(B).
Recommendation
Treatment introduction for patients with early RA should 
be early (in the fi rst few months after symptom onset) to 
increase the clinical response rate (NNT: 2–4) and reduce 
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radiological joint damage progression in the early years of 
treatment.
3. Does corticosteroid use in early-stage disease 
improve patient outcomes?
Improvements in infl ammation and pain are the best-
known and expected effects of corticosteroids in RA. How-
ever, some studies have indicated that corticosteroids, 
when combined with DMARDs, can modify the course of 
the disease14(A) 66(D).
Most studies on the use of corticosteroids in RA treat-
ment suggest the use of prednisone or prednisolone at low 
doses (≤ 15 mg/day). There are no comparative studies that 
have preferentially indicated higher doses at the beginning 
of treatment14(A) 66(D).
Because corticosteroids have many side effects, their 
usage should be kept to a minimum. If corticosteroid use 
for three or more months is foreseen, calcium and vitamin 
D supplements should be taken. The use of antiresorptive 
drugs such as bisphosphonates could be considered in pa-
tients with risk factors as determined by fractures or bone 
densitometry results50(B).
Gastric protection via proton pump inhibitors is recom-
mended for patients who concomitantly use corticoste-
roids and NSAIDs67(D).
The use of intra-articular corticosteroids can be consid-
ered at any treatment stage during which the disease re-
mains active in a small number of joints67(D). In patients 
with early RA (less than 12 months of symptoms) and in-
volvement of the MCP joints, the use of MTX in combina-
tion with intra-articular methylprednisolone infi ltration 
can reduce bone loss in the infl amed joints122(B).
Prednisone (12.5 mg/day for two weeks and 6.25 mg/day 
for 12 months), when combined with MTX (15 mg/month), 
led to an increase of 43.4% (NNT: 2) in the 6-month remis-
sion rate (according to DAS) in patients with early RA (less 
than 12 months of disease)115(B).
In patients with early-stage arthritis (less than 16 weeks 
of symptoms), the use of an intramuscular glucocorticoid 
(single injection of 120 mg methylprednisolone) offered no 
benefi t with respect to symptom remission or RA develop-
ment at 52 weeks123(B).
The use of 1–4 mg of prednisone per day for 24 weeks re-
duced the risk of loss of treatment adherence due to a lack 
of effi cacy by 31% (NNT: 3) in RA patients124(A).
In RA patients, combined treatment with MTX (15 mg 
weekly) and prednisone (60 mg per day with gradual reduc-
tion) for 24 months reduced radiological progression and 
improved functional responses (HAQ) but increased the 
number of patients with a loss of treatment adherence by 
7% (number needed to harm – NNH: 14)125(A).
The combination of MTX (15 mg/week) and prednisone 
(60 mg/day) led to an increase in the 24-month remission 
rate (DAS ≤ 2.4) of 18% (NNT: 6), increases in clinical re-
sponses (ICR) and functional capacity (HAQ), and reduc-
tions in radiographic progression in RA patients, compared 
to treatment without prednisone56(B) 126(A). However, de-
spite the lack of increased adverse events, patients report-
ed greater intolerance to this combination127(B).
The combination of DMARDs and prednisolone (7.5 mg/
day) over 24 months reduced radiological joint damage 
progression (Sharp score) and increased disease remission 
(DAS-28) by 22.7% (NNT: 4), with few adverse events in pa-
tients with early RA (less than 12 months of symptoms)128(A).
The use of budesonide (9 mg/day) or prednisone (7.5 mg/
day) in RA patients (less than 12 months of disease) for 12 
weeks caused improvements in disease activity (number of 
involved joints) and function (HAQ)129(B).
There was no increased clinical benefi t from the use of 
prednisone at 10 mg/day for 24 months in patients with 
early-stage RA. However, there is evidence for reduced ra-
diographic joint damage progression, and no increases in 
the rates of bone fractures have been reported130,131(A).
The combination of prednisolone (initial dose of 30 mg/
day and maintenance of 4.5 mg/day) and DMARDs only 
caused a reduction in radiographic injury progression 
(Larsen score) at 12 months in patients with early RA132(B).
Recommendation
The use of corticosteroids, particularly daily prednisone, in 
combination with drugs that modify the disease course, espe-
cially MTX, for 12 to 24 months offers radiological and clini-
cal benefi ts to patients with early RA. Because corticosteroids 
have many side effects, their usage should be kept to a mini-
mum, and their dose should be the smallest possible.
4. Does the prescription of anti-infl ammatory 
drugs alter the disease prognosis with regard to 
clinical and radiographic progression?
NSAIDs are useful because they decrease infl ammation and 
pain, especially early in the disease, as DMARDs are not im-
mediately effective. NSAIDs can also be used when disease 
activity is not completely controlled and when disease fl are-
ups occur47(B)65(D).
Patients who were diagnosed with RA within the past 
12 months and who initially received NSAID treatment (12 
months) alone or, if necessary, with DMARDs, had worse 
clinical responses within fi ve years than those who initially 
received DMARDs (gold sodium, chloroquine, MTX or sul-
fasalazine), as measured by ESR (in mm/hour), mean pain 
score (visual analogue scale – VAS-100 mm), articular score 
(Thompson articular index of edema and joint pain, 0–534), 
general well-being (VAS-100 mm), duration of morning stiff-
ness (maximum, 720 minutes), grip strength (kPa; measured 
with a vigorimeter), and functional disability (HAQ) (0–3)133(B). 
Of the patients who used NSAIDs for the fi rst 14 months (on 
average), 86% discontinued the treatment due to ineffective-
ness and were subsequently treated with DMARDs for an av-
erage of 42 months. Patients who remained on NSAIDs for 
fi ve years had worse clinical and radiological progressions in 
comparison to those who discontinued treatment133(B).
Furthermore, adult patients who had RA for at least six 
months and had previous clinical responses to NSAIDs had 
varying lower discontinuance rates due to ineffectiveness 
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of 12%–20% and 10%–50% after 12-week treatments with 90 
mg/day of etoricoxib or 500 mg of naproxen twice daily, re-
spectively. However, there were measurable benefi ts for pa-
tients who remained on the treatment, according to the pa-
tient global assessment scores (PGA), Investigator of Global 
Assessment of Disease Activity scores and the number of 
joints with edema134,135(A).
Patients who had been diagnosed with RA in the previous 
12 months were treated with either 1.2 g/day of sulfasala-
zine or 100 mg/day of diclofenac; 11% and 20%, respectively, 
did not complete the 12-month treatment course due to 
ineffectiveness. The number of radiographic erosions was 
signifi cantly higher in patients treated with diclofenac. Fur-
thermore, with regard to the disease activity scores (ESR and 
DAS), swollen joints, patient global assessments and HAQ, 
the patients treated with sulfasalazine had 65% to 82% bet-
ter responses than those treated with NSAIDs136(B).
Despite a discontinuation rate of 15%, the use of diclof-
enac for active RA treatment produced signifi cant responses 
at 12 weeks according to the ACR20 criteria, patient global 
assessments, VAS for pain, functional HAQ scores and joint 
swelling. CRP and ESR outcomes did not show signifi cant 
benefi ts137(A).
RA patients (duration of more than three months) who 
used different doses of celecoxib (100 mg, 200 mg or 400 mg) 
or a dose of naproxen (500 mg twice daily) showed function-
al (HAQ) and quality of life (SF-36) improvements at 12 weeks 
according to the ACR20 and also the number of involved 
joints, VAS for pain, HAQ and PGA, with no differences in 
response between these medications. However, naproxen 
produced adverse gastrointestinal events in a number of 
patients138,139(A).
Patients with RA for at least six months who used 200 mg 
of celecoxib or 75 mg of diclofenac twice daily for 24 weeks 
were found to have reduced edema, joint stiffness and PGA 
score indices with no differences between the treatments. 
However, adverse gastrointestinal events were signifi cantly 
more frequent in patients treated with diclofenac140(A).
There are indications that the combination of NSAIDs 
and DMARDs is a favorable prognostic factor for RA 
remission141(B). The chosen NSAID should be personalized, 
as there is no known superiority of any drug in this class. 
Greater control, replacement, suspension, shorter usage 
time and lower dose should be considered if there are any 
medical conditions that might be aggravated by NSAIDs 
such as previous NSAID hypersensitivity, hypertension, 
heart failure, renal failure, gastrointestinal disease, arterial 
failure, liver disease or clotting disorders48(B).
For patients with a history of gastrointestinal disease, the 
selective cyclooxygenase 2 (COXIB) inhibitors present a low-
er risk than other NSAIDs49(B). For those with a higher risk 
of cardiovascular disease, anti-infl ammatory drugs should 
generally be used with caution13(A).
Recommendation
The use of NSAIDs alone as an early treatment in patients 
with active RA produces a worse clinical response in the fi rst 
24 months than combined treatment with DMARDs and also 
suffers from a high rate of treatment discontinuation due to 
ineffi cacy. The rate of adverse gastrointestinal events asso-
ciated with treatment discontinuation, the short treatment 
response evaluation time, as well as the worse radiological 
clinical prognosis means that RA treatment with NSAIDs 
alone is not recommended. Apparently, the use of NSAIDs 
in combination with DMARDs during early-stage disease is a 
favorable prognostic factor for RA remission.
5. Should methotrexate be the fi rst treatment 
option?
MTX is an immunomodulatory agent that acts by inhibiting 
the synthesis of DNA, RNA, thymidylate and proteins. In RA, 
the anti-infl ammatory effects of MTX appear to be at least 
partly related to the modulation of adenosine metabolism 
and to possible effects on tumor necrosis factor (TNF) ac-
tivity. The immunosuppressive and toxic effects of MTX are 
due to the inhibition of dihydrofolate reductase, an enzyme 
involved in folic acid metabolism that prevents the reduc-
tion of dihydrofolate to active tetrahydrofolate. The time to 
maximum concentration is 1–5 hours orally (OR) and 30–60 
minutes intramuscularly (IM) or subcutaneously (SC). After 
administration, 40% - 90% is eliminated renally in an unal-
tered form68(D). MTX is currently considered the standard 
drug for RA treatment69(D). Its abilities to reduce the signs 
and symptoms of RA activity and improve patient function-
ality have been demonstrated15(A). Additionally, MTX reduc-
es the progression of radiographic lesions.
An initial dose of 10–15 mg/week MTX, administered 
orally or parenterally (IM or SC), is recommended. If disease 
improvement or control is not observed in response to the 
initial dose, the dose should be gradually increased every 2–4 
weeks to a fi nal dose of 20–30 mg/week, preferably within 
the fi rst 12 weeks. Parenteral presentation may be indicated 
in patients with gastrointestinal intolerances or inadequate 
responses to the oral form70(D).
The adverse events most frequently reported in response 
to MTX are anemia, neutropenia, nausea and vomiting, mu-
cositis, and elevated liver enzyme levels. Less frequent man-
ifestations include interstitial pneumonia. It is contraindi-
cated in patients with renal failure, liver disease, alcoholism, 
bone marrow suppression and in women of childbearing 
potential who are not using contraception. Pregnancy and 
breastfeeding are formally contraindicated in MTX-treated 
patients. MTX should be used with caution in patients with 
mild lung disease and avoided in patients with moderate or 
severe pulmonary disorders70(D).
It has been suggested that MTX administration should be 
combined with folic acid at doses of 5–10 mg/week, given 
24–48 hours after MTX, to minimize adverse events70(D).
Recommendation
The effi cacy of MTX for the treatment of active and early RA 
is well established. MTX is currently considered the standard 
drug for RA treatment. Its abilities to reduce the signs and 
symptoms of RA activity and improve patient functionality 
have been demonstrated. MTX also reduces the progression 
of radiographic lesions.
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6. Are other DMARDs such as lefl unomide, 
sulfasalazine and gold sodium equivalent to 
MTX in terms of safety and effi cacy for disease 
treatment?
Lefl unomide
Lefl unomide is an immunomodulatory agent that inhibits the 
enzyme dihydroorotate dehydrogenase, which is involved in 
pyrimidine synthesis, and thus presents with antiprolifera-
tive activity. It is absorbed via the gastrointestinal tract, and 
biotransformation most likely occurs in the liver and gastro-
intestinal wall, where lefl unomide is mainly transformed into 
M1, the active metabolite responsible for all lefl unomide-asso-
ciated actions. The time to maximum concentration (peak) of 
M1 is 6-12 hours, and elimination is renal and intestinal71(D).
Lefl unomide improves disease activity and patient quality 
of life and reduces radiographic progression18(A) 53(B).
Lefl unomide is prescribed at a dose of 20 mg/day (OR)18(A) 
53(B) 71(D), although a dose of 20 mg on alternate days may be 
used.
Adverse events in response to lefl unomide include nausea, 
vomiting, abdominal pain and diarrhea, abnormal liver en-
zyme levels, rash and hypertension71(D). It is contraindicated 
in women of childbearing potential who are not using contra-
ception, as well as in patients with renal and hepatic disease. 
Pregnancy and breastfeeding are formally contraindicated in 
lefl unomide-treated patients, and its suspension is recom-
mended for two years before a possible pregnancy. In cases 
of complications, especially in pregnancy, lefl unomide can be 
eliminated by the administration of cholestyramine, given in 
8-g doses three times daily for 11 days71(D).
A comparison between MTX (25 mg/day) and lefl unomide 
(20 mg/day) combined with prednisone, given for 24 weeks, 
showed no difference in clinical response in patients with RA 
for more than 2.4 years as measured by DAS-28142(B).
In a systematic review of randomized controlled trials 
(RCTs) that studied the use of lefl unomide in patients with 
active RA, it was concluded that there was no difference in 
clinical outcomes compared to MTX143(A) .
In patients with active RA, the use of lefl unomide (20 mg/
day) for four months showed no differences in clinical (ICR 
and VAS) or functional (HAQ) responses compared with MTX 
(15 mg/week) but showed better results according to MR im-
aging criteria144(A). However, this comparison was performed 
with submaximal doses of MTX.
There was no difference between lefl unomide (20 mg/day) 
and MTX (15 mg/week) with respect to clinical response (ICR) 
in RA patients after a 24-month treatment, but functional re-
sponses (HAQ) were higher in response to lefl unomide145(A).
In a 24-month RA treatment with lefl unomide (20 mg/
day) or MTX (15 mg/week), the results were similar for the 
two forms of treatment with regard to ICR, joint swelling, 
overall evaluations and radiological responses146(A). The func-
tional response (HAQ) was also similar for the two forms of 
treatment146(A).
Lefl unomide treatment (20 mg/day) in patients with active 
RA produced similar effects to MTX (15 mg/week) with regard 
to radiological disease progression147(B).
The clinical (ICR) and radiological responses in patients 
with RA for more than 6 months were similar when the pa-
tients were treated for 52 weeks with lefl unomide (20 mg/day) 
or MTX (7.5 mg/week)148(A). However, the functional results in 
some components of the HAQ and SF-36 were better in the 
lefl unomide-treated patients149(A). Again, we must emphasize 
that the dose of methotrexate used in this study was lower 
than the doses typically used for RA treatment.
Patients with active RA showed a greater tolerance to MTX 
treatment (15 mg/week) than to lefl unomide treatment (20 
mg/day), but the clinical and radiological effi cacies over 12 
months were similar150,151(A) 152(B).
Sulfasalazine
Sulfasalazine belongs to the group of salicylates and sulfon-
amides. It is produced by intestinal bacteria from sulfapyri-
dine and 5-aminosalicylic acid. Sulfapyridine has multiple 
immunomodulatory effects, including the inhibition of pros-
taglandin production, various neutrophilic and lymphocytic 
functions and chemotaxis. It also inhibits folate-dependent 
enzymes. The peak serum concentration of sulfasalazine is 
approximately 1.5–6 hours, and it has an elimination half-life 
of 5–10 hours. The drug is metabolized in the gastrointesti-
nal tract (via the intestinal fl ora), and its excretion is renal 
(75%–91%)16(A).
Sulfasalazine is considered to be more effective than a 
placebo with regard to disease activity reduction, pain con-
trol and global clinical assessments. Its clinical effi cacy 
and interference with radiographic progression have been 
confi rmed16(A).
Sulfasalazine is usually prescribed at a dose of 1-3 g/day 
(OR)16,17(A).
Side effects include gastrointestinal intolerance (anorexia, 
nausea, vomiting), rash, elevated liver enzyme levels, oral ul-
cers and myelosuppression (leukopenia with neutropenia). 
Hypersensitivity pneumonitis, neurological manifestations 
and changes in male fertility are rarely observed. Most effects 
are benign and reversible with drug withdrawal17(A).
Salicylates or any components of the sulfasalazine formu-
la are contraindicated in patients with known sulfonamide 
hypersensitivity and individuals with porphyria16,17(A).
There was no difference in the clinical responses (DAS ≤ 2.4) 
of RA patients who received MTX monotherapy (15 mg/week) 
or sulfasalazine (40 mg/kg/day), although the combination of 
the two forms of treatment produced better outcomes at 18 
months14(A).
In patients with RA for less than 12 months, sulfasalazine 
treatment (2 g/day) produced similar results (DAS, EULAR and 
ACR) as MTX treatment (15 mg/week) over 52 weeks; however 
the combined therapies appeared to increase the treatment 
benefi ts, according to DAS measurements66(D).
Gold sodium
Gold sodium, specifi cally in injectable forms (aurothioglucose 
and aurothiomalate), is able to reduce both the constitutional 
and articular symptoms and slow the radiographic evolution 
of RA22(A). It can be used alone or in combination with other 
agents23(A).
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The usual dose of gold sodium is 50 mg/week; the treat-
ment is usually initiated at 25 mg/week, and it is possible to 
increase the application interval to biweekly and monthly 
doses after the symptoms are controlled. The cumulative 
dose should not exceed 3 g22,23(A).
Its toxicity profi le includes myelotoxicity (particularly 
thrombocytopenia), oral ulcers, skin reactions (exfoliative 
dermatitis), nephropathy (possibly including involving pro-
teinuria) and interstitial lung disease22,23(A).
Although it has been recommended in recent interna-
tional reports66(D), gold sodium is currently used very rarely 
in Brazil due to its adverse effects and the diffi culty of drug 
acquisition in this area.
A comparison between MTX (15 mg/week) and gold so-
dium (50 mg/week) for the treatment of RA patients (dura-
tion > 4 months) demonstrated improved clinical outcomes 
(swelling and stiffness) in the fi rst year for patients treated 
with gold sodium but similar outcomes in the third year of 
follow up. There was greater toxicity in the fi rst and third 
year (increased risk of 38%; NNH: 3)98,153(A) and similar results 
with regard to radiological progression in one154(A) and three 
years22(A).
Gold sodium (50 mg/week) has a similar treatment effi cacy 
(clinical and functional) as MTX (20 mg/week) for RA patients 
but also has an increase in toxicity of 24% (NNH: 4 )154(A).
Recommendation
Lefl unomide, sulfasalazine and gold sodium appear to have 
similar effi cacies to that of MTX for the treatment of active 
RA; however, there is a greater risk of intolerance and toxicity 
and discontinuation with these drugs relative to MTX.
7. Are antimalarial drugs effective in RA 
treatment?
Antimalarials have been used in RA treatment for more than 
50 years. These drugs are safe and effective, especially for 
early and mild forms of RA. The action mechanism is still 
unclear, although it appears to involve multiple factors, in-
cluding anti-infl ammatory activity (stabilization of lysosomal 
membranes, inhibition of lysosomal enzymes and chemotax-
is and polymorphonuclear phagocytosis) and interference in 
prostaglandin production, among others19,20(A).
The two available forms are chloroquine diphosphate and 
hydroxychloroquine sulfate; the latter is preferred due to its 
better safety profi le, especially with regard to ophthalmologic 
factors. The maximum daily doses of chloroquine phosphate 
and hydroxychloroquine sulfate are 4 mg/kg/day and 6 mg/
kg/day orally, respectively, depending on the ideal weight of 
the patient. The onset of action is slow and requires three to 
four months to achieve peak effi ciency in approximately 50% 
of patients.
The side effects are diverse and include gastrointestinal 
intolerance (nausea, vomiting, abdominal pain), skin hyper-
pigmentation, headache, dizziness, myopathy and retinopa-
thy. The latter is infrequent, but regular ophthalmologic mon-
itoring is indicated (baseline and annually after fi ve years, or 
annually from the outset in patients with risk factors such 
as those with renal or hepatic impairment or maculopathy, 
those who are elderly or those with a cumulative dose greater 
than 1,000 g of hydroxychloroquine sulfate or 460 g of chloro-
quine diphosphate)72(D).
Hydroxychloroquine was more effective than a pla-
cebo in reducing the analyzed clinical and laboratory pa-
rameters (ESR), although in isolation it did not alter radio-
graphic progression19-21(A). Similar results were observed 
with chloroquine, which is less expensive. These drugs are 
contraindicated in patients with retinal and visual fi eld 
abnormalities21(A)72(D).
Although these drugs are traditionally used in Brazil, often 
in combination with other DMARDs, antimalarials are cur-
rently considered less potent drugs and should only be used 
in early cases of RA or undifferentiated arthritis with a low 
erosion potential.
Several therapeutic regimen studies have included hy-
droxychloroquine; however, these studies did not permit a 
specifi c and individualized analysis of the effects of hydroxy-
chloroquine in early-stage RA treatment.
In RA patients who did not respond to NSAID use, hydroxy-
chloroquine treatment (200-400 mg/day) for 12 weeks led to 
reduced swelling, stiffness and joint pain (20%, 23% and 26%, 
respectively) and increased clinical responses (ICR)(ACR20) of 
20% (NNT: 5). There was no increase in adverse events155(A).
Hydroxychloroquine treatment (7 mg/kg/day) in RA pa-
tients (disease duration less than 24 months) for 36 weeks 
reduced joint involvement and pain and improved functional 
responses20(A). A follow-up after 36 months showed better 
outcomes for these patients than for those who were treated 
later (after nine months)156(B).
There were no differences in treatment responses and 
numbers of adverse events between three different doses of 
hydroxychloroquine (400 mg/day, 800 mg/day or 1.2 g/day) 
during a 24-week period in patients with early-stage RA157(B).
Patients (more than six months of RA) who were previously 
treated with a combination of MTX (15 mg/week) and hydroxy-
chloroquine (400 mg/day) for 24 weeks have benefi ted from a 
12-week maintenance regimen of hydroxychloroquine158(B).
In early-stage RA patients, hydroxychloroquine treatment 
(400 mg/day for 24 weeks) reduced joint involvement by 10% 
(NNT: 10) and pain by 19% (NNT: 5), while overall patient and 
physician evaluations improved by 16% (NNT: 6) and 12% 
(NNT: 8), respectively. There was an increase in adverse events 
in 13% of patients (NNT: 8)19(A).
The combination of MTX (15 mg/week) and hydroxychlo-
roquine (200 mg/day) for six months for the treatment of ear-
ly-stage RA patients increased clinical responses and reduced 
pain and joint impairment when compared with hydroxy-
chloroquine treatment alone159(B).
The addition of hydroxychloroquine (400 mg/day) to the 
treatment regimens of patients with partial responses to gold 
sodium (six months) added no benefi ts with respect to pain 
and joint involvement160(B).
Recommendation
The treatment of early-stage RA with hydroxychloroquine 
at doses of 200–400 mg/day provides benefi ts related to pain, 
joint involvement and clinical responses, although the evi-
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dence for these benefi ts is weak, whether due to improper 
measures used to demonstrate the benefi ts, the reduced size 
of the benefi ts or weak supporting evidence. Although these 
drugs are traditionally used in Brazil, often in combination 
with other DMARDs, antimalarials are currently considered 
less potent drugs and should be used in early cases of RA or 
undifferentiated arthritis with low erosion potential.
Biologic DMARDs
One of the most important advances in RA therapy has been 
the development of biologic DMARDs. While these medica-
tions effectively control RA, studies are needed to determine 
their long-term safety. The following biologic DMARDs are 
approved by the National Agency for Sanitary Surveillance 
(Agência Nacional de Vigilância Sanitária (ANVISA)) for use 
in Brazil:
• TNF blockers: adalimumab, certolizumab, etanercept, inf-
liximab and golimumab;
• B lymphocyte depletion: rituximab;
• Costimulatory blocker: abatacept;
• Interleukin-6 (IL-6) receptor blocker: tocilizumab.
These drugs are indicated for patients with persistent dis-
ease activity despite treatment with at least two synthetic 
DMARD regimens (at least one in combination with DMARDs). 
Biologic agents must be combined with a DMARD, preferably 
MTX. However, one biologic DMARD may be prescribed earlier 
in the course of RA treatment, especially in cases of disease 
with signs of poor prognosis (a high number of involved joints, 
radiographic erosions in early-stage disease, high rheumatoid 
factor and/or anti-CCP levels); this exception is described be-
low.
Social, educational and demographic characteristics of 
different macro-regions of Brazil, including diffi culties in 
the administration of SC medications for certain patients 
and their families, as well as the absence of infusion centers 
for the administration of IV medications in certain places, 
may determine the choice of biologic DMARDs. Public or 
private drug dispensing and infusion centers should inform 
patients and families about the appropriate conditions for 
each medication or send them directly to the infusion sites 
to avoid losses in treatment effi cacy. It is recommended 
that these drugs be used as indicated and monitored by a 
rheumatologist78(D).
Biologic DMARDs should not be combined due to the po-
tential risk of serious infection.
8. Is the introduction of biologic therapy 
with anti-TNF drugs such as adalimumab, 
certolizumab, etanercept, infl iximab and 
golimumab effective and safe for RA patients?
Currently, the most commonly used biologic DMARDs are 
TNF blockers. TNF is a potent infl ammatory cytokine that is 
expressed in large amounts in the serum and synovial fl uid 
of RA patients. TNF promotes the release of other cytokines, 
particularly IL-1, IL-6 and IL-8, and stimulates protease pro-
duction. TNF inhibition has been shown to be an effective and 
rapid method of controlling disease activity79(D).
In terms of effectiveness, no evidence suggests the supe-
riority of any of the 5 anti-TNF agents approved in Brazil for 
RA treatment55,56 (B).
Anti-TNFs should be used in combination with MTX or other 
DMARDs because the combined use of these drugs is safe and 
effective and provides rapid control of disease activity, com-
pared to anti-TNF monotherapy. In patients who have contrain-
dications to the use of synthetic DMARDs, anti-TNF may even-
tually be prescribed as a monotherapy77(D) 26-31,43,44(A) 45,57,58(B).
Adalimumab
Adalimumab is a human monoclonal anti-TNF antibody pre-
scribed for SC use at a biweekly dose of 40 mg28,33-37,45(A). A 
52-week follow-up of RA patients who were treated with MTX 
and adalimumab (40 mg or 20 mg biweekly) showed increased 
clinical responses (ACR50) of 32% (NNT: 3) and 28.2% (NNT: 
4), respectively, with combination therapy compared to MTX 
monotherapy. There was also a reduction in radiographic pro-
gression and functional improvement (HAQ) with the combi-
nation therapy, with no increase in adverse events161(A) 162(B).
Treatment of RA patients with a combination of biweekly 
40 mg adalimumab and MTX (20 mg weekly) increased clini-
cal responses (ACR50) by 21% (NNT: 5) and 16% (NNT: 6) com-
pared to adalimumab and MTX monotherapies, respectively. 
There was also a reduction in radiographic progression, as 
well as an increase in clinical remission (DAS-28 ≤ 2.6) of 20% 
(NNT: 5) and of 22% (NNT: 5) compared to adalimumab and 
MTX monotherapy, respectively57(B).
The clinical response (ACR50) obtained with biweekly 40 
mg adalimumab for 24 weeks in RA treatment concomitantly 
with the use of synthetic DMARDs increased clinical respons-
es (ACR50) by 17.6% (NNT: 6) and did not increase the risk of 
adverse events or serious adverse events34(A).
The combination of adalimumab in doses of 20 mg, 40 mg 
or 80 mg and MTX (15 mg/week) for 24 weeks produced in-
creases in clinical response (ACR50) of 23.8% (NNT: 4), 47.1% 
(NNT: 2) and 30.4% (NNT: 3), respectively, compared to MTX 
monotherapy, with no difference in adverse events163(A).
Certolizumab
Certolizumab pegol is a Fab fragment of a humanized, high-
affi nity anti-TNF antibody linked to two polyethylene glycol 
molecules. It is prescribed for SC use at a biweekly dose of 400 
mg during weeks 0, 2 and 4 and at a dose of 200 mg every two 
weeks or 400 mg every four weeks thereafter30,31,37(A).
Certolizumab treatment at 200 mg or 400 mg biweekly for 
52 weeks, combined with MTX (15 mg/week), increased clini-
cal responses (ACR50) by 29.5% (NNT: 3), reduced the progres-
sion of radiological lesions and increased functional respons-
es (HAQ) when compared to MTX monotherapy. There was a 
35% increase in serious adverse events (NNH: 3) with both cer-
tolizumab regimens. There were no differences in response or 
adverse events between the certolizumab doses164(A). There 
was also evidence of a positive impact on patient quality 
of life 30(A). According to RAPID3 criteria, there was an in-
crease in remission of 32% (NNT: 3) in patients treated with 
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certolizumab165(B), and clinical responses were also higher 
than the hybrid ICR score166(B).
Etanercept
Etanercept is a fusion protein composed of the TNF soluble re-
ceptor that binds more strongly to the Fc region than to the IgG. 
This therapy is prescribed at a weekly dose of 50 mg SC36(A) 
43,45,59(B).
At a 52-week follow-up of RA patients, it was concluded that 
a combined treatment of etanercept (50 mg/week) and MTX 
(15 mg/week) increased remission by 22.5% (NNT: 5) and re-
duced radiographic lesion progression when compared to MTX 
monotherapy105(A). This effect was maintained after 24 months 
of follow-up45(B).
The use of etanercept (50 mg/week) for 24 weeks in patients 
with active RA, with or without sulfasalazine (2–3 g/day), dem-
onstrated superior clinical responses (ACR50) of 32% to 38% 
(NNT: 3); however there was a 19.6% increase in the number 
of infections (NNH: 5), as well as infusion reactions167(A). At a 
24-month follow-up, there was less treatment discontinuation 
due to lack of effi cacy in patients undergoing etanercept treat-
ment (NNT: 2), and the benefi ts were permanently sustained. 
There was, however, an increase in infectious adverse events 
and adverse events from local application168(B).
An ACR-N analysis of the clinical responses of RA patients 
after 24 weeks of treatment with etanercept (50 mg/week) com-
bined with MTX (15 mg/week) showed a 6.1% increase (NNT: 
17)169(A). After 52 weeks, remission remained evident in 18.2% 
(NNT: 6) and 12.4% (NNT: 8) of patients who received etaner-
cept alone or combined with MTX, respectively170(B). Addition-
ally, after 52 weeks, there was a reduction in radiological lesion 
progression in these patients171(B).
Of the RA patients who were treated with etanercept (50 
mg/week), 51% showed a clinical response (ACR50) after three 
years, and this response was maintained after fi ve years. There 
was a reduction in disease activity (DAS < 2.4) in 44% of the 
patients. However, 44% of the patients experienced episodes 
of infection, which can induce cancer and treatment-related 
death172,173(C).
After a 12-month treatment, the use of 50 mg etanercept per 
week conferred greater benefi ts to RA patients than a dose of 
20 mg/week. When compared with MTX (15 mg/week), the clin-
ical responses (ACR50) was similar, although there were great-
er radiological lesion progression and more adverse events in 
MTX-treated patients174(A). These results were maintained at a 
24-month follow-up, and the functional responses (HAQ) were 
better in 18% (NNT: 6) of the etanercept-treated patients59(B).
In patients with inadequate responses to a combination of 
MTX (15 mg/week) and etanercept (50 mg/week), an increased 
dose of etanercept (100 mg/week) did not improve the patient 
clinical responses175(A).
Infl iximab
Infl iximab is a monoclonal mouse-human chimeric anti-TNF 
antibody that is prescribed at an initial dose of 3 mg/kg, given 
IV, followed by the same dose (3 mg/kg) in the second and 
sixth weeks and every eight weeks thereafter76(D). In patients 
with insuffi cient responses, the dose can be increased to 5 
mg/kg by infusion, or the dose interval can be reduced. Larger 
doses add little therapeutic benefi t and increase the risk of in-
fectious complications; thus, this approach should be avoided 
in RA treatment27,58(B) 36,38,44(A). 
In RA patients who are nonresponsive to MTX (15 mg/week), 
when combined with infl iximab (3 mg/kg initially at weeks 0, 
2 and 6 and every 8 weeks thereafter), there were increases in 
clinical response according to the EULAR and ACR50 criteria 
of 14% (NNT: 7) and 10% (NNT: 10), respectively, compared to 
a combination of sulfasalazine and hydroxychloroquine58(B).
Treatment of RA patients with a combination of infl iximab 
(3 mg/kg or 10 mg/kg at weeks 0, 2 and 6, and every 8 weeks 
thereafter) and MTX (15 mg/week) for 22 weeks increased 
clinical responses by 22.4% (NNT: 5) and 25.7% (NNT: 4) and 
remission (DAS-28 < 2.6) by 17.0% (NNT: 6) and 18.0 % (NNT: 
6), respectively. There was no difference in response between 
the two infl iximab dose regimens. There was no difference in 
adverse events related to infl iximab treatment, regardless of 
the dose176(A).
Treatment of RA patients with a combination of 3 mg/kg 
or 6 mg/kg infl iximab (initially at weeks 0, 2 and 6, and every 
8 weeks thereafter) and MTX (15 mg/week) for 54 weeks in-
creased ACR-N clinical responses by 12.5%  (NNT: 8) and 20.3% 
(NNT: 5), respectively, ACR50 clinical responses by 13.5% (NNT: 
7) and 18.3% (NNT: 6), reduced the progression of radiological 
damage (Sharp score) and increased functional responses by 
6.2% (NNT: 16) and 16.0% (NNT: 6), respectively. No difference 
in effi cacy was observed between the two treatment regi-
mens. There were increases in the rates of serious adverse 
events of 3.5% (NNH: 30) and 2.9% (NNH: 33) with the doses of 
3 mg/kg and 6 mg/kg, respectively177(A).
Golimumab
Golimumab is a human monoclonal anti-TNF antibody that is 
administered at a dose of 50 mg/month SC44,60(B).
Treatment of RA patients with a combination of MTX (15 
mg/week) and golimumab (50 mg every 4 weeks) for 24 weeks 
increased remission rates (ACR50) by 10.9% (NNT: 10) and 13.9% 
(NNT: 7) (DAS-28 ≤ 2.6) compared to MTX monotherapy. There 
were no increases in adverse events for this combination over 
monotherapy44(B). The radiological response (Sharp score) was 
also higher in response to golimumab (50 mg) plus MTX178(B).
In RA patients, a 14-week treatment with a combination 
of MTX (15 mg/week) and golimumab (50 mg or 100 mg ev-
ery four weeks) yielded increases of 25.0% (NNT: 4) and 19.4% 
(NNT: 5), respectively, in clinical responses and of 14.2% (NNT: 
7) and 16.5% (NNT: 6), respectively, in remission (DAS-28). 
However, there was an increase in adverse events and serious 
adverse events with the 100 mg dose of golimumab compared 
to the 50 mg dose179(A). After a 52-week follow-up, there were 
no differences with respect to monotherapy, although the 
clinical response and remission rates were maintained43(B).
After a 24-week treatment with a combination of golim-
umab (2 mg/kg or 4 mg/kg) and MTX, the proportion of pa-
tients who achieved clinical responses (ACR50) increased by 
9.3% (NNT: 10) and 17.7% (NNT: 6), respectively, compared to 
MTX monotherapy. Remission (DAS-29 ≤ 2.6) over the same 
period was greater only with a golimumab dose of 4 mg/kg. 
There were no differences in adverse events and serious ad-
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verse events between the combination of MTX and golimum-
ab and MTX monotherapy180(A).
RA treatment with a combination of MTX and golimumab 
(50 mg or 100 mg every two or four weeks for 16 weeks) re-
sulted in similarly increased clinical response rates (ACR50) 
and remission rates (DAS-28 ≤ 2.6) with all regimens; the only 
treatment regimen that showed no benefi t compared to MTX 
monotherapy was a 50-mg dose every four weeks. There were 
no differences in adverse events between the various forms 
of treatment181(A).
Adverse events and contraindications of TNF blockers
Adverse events include infusion reactions to IV drugs (fever, 
chills, chest pain, blood pressure fl uctuation, dyspnea, rash 
and/or hives) and manifestations at SC drug injection sites 
(erythema, itching, local pain and/or hives). These drugs in-
crease the risk of infections, especially in the fi rst year of use 
(including serious infections and those caused by intracellular 
pathogens such as tuberculosis bacillus, listeria, histoplasma, 
atypical mycobacteria, legionella) cardiac dysfunction, demy-
elinating diseases, autoimmune phenomena (autoantibody 
production), cutaneous vasculitis, interstitial lung disease 
and a possible increased risk of lymphoma37,39(A) 61,62(B).
Human anti-chimeric antibodies (HACA) can occur in re-
sponse to all drugs in this class, but their effects on treatment 
effi cacy are uncertain63,64(B).
Anti-TNF drugs are contraindicated in women who are 
pregnant or breastfeeding; in patients with class III and IV 
congestive heart failure, according to the New York Heart As-
sociation classifi cation; in patients with infection; or in those 
who have a high risk of infection development (chronic ulcers 
of the lower limbs, septic arthritis in the past 12 months), re-
current pulmonary infections, multiple sclerosis, or current 
or previous cancer diagnoses (less than fi ve years). Patients 
should be carefully monitored for the possible emergence 
of signs of infection, which should be treated promptly and 
immediately39(A) 61,62(B).
Recommendation
RA patients can be treated with anti-TNF biologic DMARDs, 
including adalimumab (40 mg SC every two weeks), certoli-
zumab (400 mg SC every two weeks at weeks 0, 2 and 4 and 200 
mg every two weeks thereafter or 400 mg every four weeks, or 
monthly), etarnecept (50 mg SC every two weeks), golimumab 
(50 SC every four weeks or monthly), or infl iximab (3 mg/kg IV 
at weeks 0, 2 and 6 and every 8 weeks thereafter). All anti-TNF 
biologic DMARDs should be preferentially prescribed in combi-
nation with MTX (15 mg weekly) or another synthetic DMARD 
to achieve clinical, radiological and functional benefi ts and 
remission. There may be an increased risk of serious adverse 
events and local reactions to treatment administration.
9. Is rituximab a safe and effective alternative 
treatment for RA patients?
Rituximab is a chimeric monoclonal antibody directed against 
CD20+ lymphocytes. It is indicated for patients with moderate 
to severe active RA who failed to respond to anti-TNF agents. 
Rituximab is administered at a dose of 1,000 mg in two IV 
infusions at 14-day intervals. Each infusion is preceded by a 
dose of 100 mg of IV methylprednisolone 60 minutes before 
the rituximab, as well as 1 g of paracetamol and antihista-
mine to decrease the severity and frequency of infusion reac-
tions81-83(A) 86(C).
Given the severity of the condition, it should be noted that 
reports have linked the occurrence of progressive multifocal 
leukoencephalopathy to rituximab use182(C).
Rituximab is preferentially used in combination with MTX 
and can be prescribed in combination with other DMARDs. 
It is important to stress that there might be a delay of 3–4 
months before the onset of symptomatic improvement81-83(A). 
Rituximab induces better therapeutic responses in individu-
als who are seropositive for RF and/or anti-CCP84(B).
Should the disease reactivate, individuals with good treat-
ment responses can be subjected to new courses of rituximab 
at intervals of no less than six months81-83(A) 86(C).
The most frequent adverse events are infusion reactions, 
which occur in 35% of patients during the fi rst infusion and 
approximately 10% during the second infusion. Infectious 
complications may occur, as well as interstitial pneumonia, 
neutropenia and thrombocytopenia81-83(A) 86(C).
In RA patients, treatment with rituximab (two IV 500 g dos-
es at 15 day intervals) combined with MTX (10–25 mg/week) 
and etanercept (50 mg/week) or adalimumab (40 mg every 
15 days) for 24 weeks did not cause an increase in adverse 
events, including serious adverse events, relative to the pla-
cebo combined with MTX. There were increased risks of 22% 
(NNH: 5) for infusion reactions and of 15% (NNH: 7) for grade 
three infections. There were no differences in the clinical re-
sponse (ACR50) or remission rates (DAS-28 < 2.6)183(A).
Treatment of RA patients (disease duration of 8 weeks to 
4 years) over 52 weeks with 1 g or 2 g of rituximab combined 
with MTX increased clinical responses (ACR50) by 17% and 
23%, respectively, and remission rates (DAS-28 ≤ 2.6) by 20% 
and 23%, respectively. There were also increases in function-
al response (HAQ), and there were no increases in adverse 
events184(A).
Treatment of RA patients whose conditions were non-
responsive to MTX treatment with 1 g or 2 g rituximab in-
creased the clinical response rate (ACR50) by 17% (NNT: 6) 
after 24 weeks. There was no increase in adverse events82(A).
A comparison of 1-g, 1-g escalated to 2-g after 24 weeks 
and 2-g rituximab doses for the treatment of RA patients (with 
inadequate responses to MTX) after 48 weeks demonstrated 
similar clinical responses between the treatments (ACR50), a 
higher EULAR clinical response to the 2-g dose, compared to 
the 1-g dose and a higher remission rate (DAS-28 < 2.6) with 
the 1-g dose, compared to the escalated dose. There were no 
differences in adverse events185(A).
The treatment of anti-TNF-α and MTX-nonresponsive RA 
patients with 1 g rituximab led to reduced radiological dis-
ease progression, decreased pain (FACIT-F) and improved 
functional responses (HAQ) and quality of life (SF-36) after 24 
weeks83,186(A). The clinical responses (ACR50 and EULAR) in-
creased by 22% (NNT: 5) and 43% (NNT: 2), respectively81(A).
Treatment of RF-positive RA patients with a combination 
of rituximab and MTX for 24 weeks resulted in increased clin-
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ical response rates that (ACR50) ranged from 10%–20%, com-
pared to monotherapy. A greater number of patients did not 
require additional treatment for 48 months, due to the posi-
tive effects on functional capacity (NNT: 4)187(A).
In patients who were nonresponsive to synthetic DMARD 
treatment, the use of 1 g or 2 g rituximab for 24 weeks in-
creased the proportion of patients with clinical responses 
(ACR50 or EULAR) by 20% and reduced disease activity (DAS-
28)188(A).
The combination of rituximab (1 g) and MTX (10 mg/week) 
for the treatment of RA patients produced better results after 
24 weeks than monotherapy with either of these drugs, in-
creased the clinical response rates (ACR50) by 10%–30%, and 
increased clinical responses (EULAR) and rates of disease re-
mission (DAS-28). There were no differences in the numbers 
of adverse events189(A).
Recommendation
In RA patients with inadequate responses to MTX or other 
synthetic DMARDs and anti-TNF, the use of rituximab (1-g 
and 2-g doses), primarily in combination with MTX, improved 
clinical, radiological and functional progress while increasing 
the risk of adverse events.
10. Is tocilizumab proven for use in RA treatment?
Tocilizumab is a humanized monoclonal antibody that binds 
to the IL-6 receptor, thus inhibiting the biological effects of IL-
6. It can be used alone or in combination with MTX or other 
DMARDs. The incidence of infections and serious infections 
with tocilizumab is equivalent to that of other biologic agents. It 
is prescribed at a dose of 8 mg/kg IV every four weeks87,88(A) 96(B).
Tocilizumab can cause dose-dependent adverse events 
such as neutropenia, thrombocytopenia and elevated trans-
aminase levels. There may even be elevated levels of total 
and low-density lipoprotein (LDL) cholesterol, as well as an 
increased risk of infections87,88(A) 96(B). Tocilizumab should be 
avoided in patients who have a greater risk of bowel perfora-
tion and those with diverticular disease of the colon89(A).
RA patients with inadequate responses to MTX have 
shown positive results in response to tocilizumab (4 mg/kg or 
8 mg/kg every four weeks for 52 weeks) with respect to clini-
cal response (ACR70), remission (DAS < 2.6), and functional 
(HAQ) and radiological (Sharp score) responses. Radiological 
disease progression was reduced by 74% and 70%, respec-
tively, compared to MTX monotherapy. There were signifi cant 
functional improvements of 15.4% (NNT: 6) and 9.9% (NNT: 
10), respectively, and a functional response of > 0.3 units was 
maintained. The clinical response rates were 6.0% (NNT: 16) 
and 3.5% (NNT: 30), respectively. Disease remission rates were 
39.3% (NNT: 2) and 22.3% (NNT: 5), respectively. There was a 
2% incidence of neoplasias in patients who received tocili-
zumab, a 2.5% incidence of severe anaphylactic reactions (4 
mg/kg), and a 5% increase in the risk of severe adverse events 
(NNH: 20)190(A).
In RA patients between six months and fi ve years, the ad-
ministration of 8 mg/kg tocilizumab every four weeks for 52 
weeks led to a reduction in radiographic disease progression 
of 15% (NNT: 7) compared to synthetic DMARDs, and this ef-
fect was greater in patients at a high risk for progression191(A). 
The clinical effi cacy (ACR50) was 51% (NNT: 2). The remission 
rate was 56% higher (NNT: 2), and the functional response 
rate improved by 28% (NNT: 4). There was an increase of 5% 
in the occurrence of serious adverse events in response to to-
cilizumab (NNH: 20) and 2% and 7% increases in cancer inci-
dence and infusion reaction rates, respectively. There were no 
differences in mild to moderate adverse events between the 
two forms of treatment191(A).
A comparison between 8 mg/kg tocilizumab, given every 
four weeks, and 15 mg/week MTX for a 24-week treatment 
of RA patients provided results in favor of tocilizumab. To-
cilizumab was found to increase the clinical response rate 
(ACR50) by 10.6% (NNT: 9) and the remission rate (DAS-28 < 2.6) 
by 21.5% (NNT: 5). The most common adverse reactions were 
infections, although no difference was observed between the 
two forms of treatment. There was an increase of 3.8% in the 
infusion reaction rate with tocilizumab (NNH: 30)96(A).
In RA patients (more than six months), treatment with 
8 mg/kg tocilizumab every four weeks in combination with 
DMARDs (MTX, chloroquine, gold sodium, sulfasalazine, aza-
thioprine or lefl unomide) produced an increased clinical re-
sponse rate (ACR50) of 29% (NNT: 3), an increase in remission 
(DAS-28 < 2.6) and a functional response rate of (HAQ) of 26% 
after 24 weeks (NNT: 4) compared to monotherapy with these 
drugs. There was an increase of 11.7% in the risk of adverse 
events (NNH: 9)192(A).
RA patients with inadequate responses to MTX showed 
positive results after treatment with tocilizumab (4 mg/kg or 8 
mg/kg every four weeks for 24 weeks) with respect to clinical 
response (ACR50), remission (DAS < 2.6), and functional (HAQ) 
response. There were signifi cant functional improvements 
with both doses. The clinical response rates were 20.0% (NNT: 
5) and 33% (NNT: 3), respectively. Disease remission rates were 
12.2% (NNT: 8) and 26.2% (NNT: 4), respectively. There were no 
differences in the various adverse events, of which infection 
was the most frequent193(A).
Recommendation
Tocilizumab treatment of RA patients, especially those with 
inadequate responses to MTX, when combined with MTX or 
synthetic DMARDs or as a monotherapy, produces effective 
clinical, functional, radiological and remission responses. To-
cilizumab is also effective in patients who are nonresponsive 
to anti-TNFs. There may be an increased risk of adverse events.
11. Is abatacept a treatment option for patients 
with RA, considering its safety and effi cacy 
profi le?
Abatacept is a CTLA-4-IgG fusion protein that acts as an inhib-
itor of T lymphocyte costimulation. It is indicated for patients 
with active RA who have experienced DMARD or anti-TNF 
agent treatment failure. Abatacept can be used in combina-
tion with DMARDs or as a monotherapy. Abatacept should be 
administered as an IV infusion over a 30-minute period and 
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should be administered at a dose of 500 mg to patients with 
a body weight less than 60 kg, 750 mg to patients between 
60–100 kg and 1,000 mg to patients greater than 100 kg. The 
next dose should be administered 2 to 4 weeks after the ini-
tial dose and every four weeks thereafter40-42(A). Abatacept 
is associated with a greater risk of infectious complications 
than a placebo, similarly to other biologic DMARDs. Infu-
sion reactions to abatacept are uncommon and are mainly 
hypersensitivity reactions that manifest as a rash or bron-
chospasms. Abatacept is contraindicated in patients with 
symptoms of chronic obstructive pulmonary disease (COPD) 
due to its exacerbation of dyspnea and the increased risk of 
infections40(A) 85(C).
Abatacept treatment (10 mg/kg every four weeks) pro-
duces benefi ts (ACR50) in 30% of patients with RA of an av-
erage 8.5-year duration. According to ACR50, for every three 
patients treated, one experiences no increase in adverse 
events194(A).
RA patients (of at least a 12-month duration) who were 
nonresponsive to MTX yielded increases in clinical response 
rates of 12.1% (NNT: 9), 9.9% (NNT: 10) and 9.1% (NNT: 11) ac-
cording to the EULAR, DAS-28 and ACR50 criteria, respective-
ly, after treatment with 500–1000 mg abatacept every 30 days 
for 12 months. The functional improvement rate (HAQ) was 
20.6% (NNT: 5). There was no increase in adverse events195(A).
In RA patients who were nonresponsive to anti-TNF-α, 
treatment with 500-1000 mg abatacept for six months led 
to a clinical response rate of 16.5% (NNT: 6; ACR50 criteria) 
and a functional response rate of 24.0% (NNT: 4). There was 
no increase in adverse events196(A). At 24 months, there were 
improvements of 32.3% and 20.3% in the clinical response 
(ACR50) and remission rates (DAS-28), respectively. The func-
tional response rate was 47.9% 197(B).
After a year of treatment with 500–1,000 mg abatacept, RA 
patients who were nonresponsive to MTX had a clinical im-
provement rate (ACR50) of 30.1% (NNT: 3). Physical function 
improved by 24.7% (NNT: 4), with no difference in the rate of 
adverse events198(A). After 24 months of treatment, the pa-
tients had a clinical improvement rate (ACR50) of 55.6% and 
a remission rate (DAS-28) of 30.9%199(B).
Recommendation
In RA patients who are nonresponsive to MTX or anti-TNF 
therapy, the use of abatacept at doses between 500–1,000 mg 
led to increased clinical responses (ACR50), remission (DAS-
28) and functional responses (HAQ) over 6–12 months, and 
these rates were maintained over a 24-month period. How-
ever, there may be an increased risk of adverse events.
12. Are there indications that some biologic 
treatment regimens are superior to others in the 
treatment of RA patients?
Treatment of RA patients with a combination of MTX (15 mg/
week) and golimumab (50 mg every four weeks) for 24 weeks 
yielded increases (ACR50) of 10.9% (NNT: 10) and 13.9% (NNT: 
7) in the remission rate (DAS-28 ≤ 2.6) compared to MTX 
monotherapy44(A).
A 52-week follow-up of RA patients who were treated with 
MTX and adalimumab (40 mg every other week) showed an 
increase (ACR50) of 32% (NNT: 3) in the clinical response rate 
compared with MTX monotherapy162(A). A decrease in radio-
graphic progression and an increase in clinical remission 
(DAS-28 ≤ 2.6) of 23% (NNT: 5) were observed in comparison to 
MTX monotherapy74(D).
At a 52-week follow-up of RA patients, it was concluded that 
treatment with etanercept (50 mg/week) in combination with 
MTX (15 mg/week) increased the remission rate (DAS-28) by 
22.5% (NNT: 5) compared to MTX monotherapy. Additionally, 
the clinical response rate (ACR50) was 22% higher (NNT: 5)105(A).
Treatment of RA patients with 3 mg/kg infl iximab (initially 
at weeks 0, 2 and 6 and every eight weeks thereafter) in com-
bination with MTX (15 mg/week) for 22 weeks increased the 
clinical response rate (ACR50) by 22.4% (NNT: 5) and the dis-
ease remission rate (DAS-28 < 2.6) by 17.0% (NNT: 6)176(A).
Treatment with 200 mg or 400 mg of certolizumab (every 
two weeks for 52 weeks) in combination with MTX (15 mg/
week) increased the clinical response rate (ACR50) by 29.5% 
(NNT: 3), compared to MTX monotherapy. The remission rate 
(DAS-28) was 16% (NNT: 6). There was an increase of 35% in 
the rate of serious adverse events (NNH: 3)164(A) 165(B).
Treatment of RA patients (disease duration between eight 
weeks and four years) for 52 weeks with rituximab (1.0 g IV 
infusion at intervals of 15 days) in combination with MTX 
increased the clinical response rate (ACR50) by 17% (NNT: 6) 
and the remission rate (DAS-28 ≤ 2.6) by 20% (NNT: 5)184(A). RA 
patients with inadequate responses to MTX who were treated 
with tocilizumab (8 mg/kg every four weeks for 24 weeks) in 
combination with MTX showed positive results with respect 
to clinical response (ACR50) and remission (DAS ≤ 2.6). There 
were signifi cant functional improvements at both doses. The 
clinical response rate was 33% (NNT: 3). The remission rate 
was 26.2% (NNT: 4). There were no differences in the various 
adverse events, of which infection was the most frequent193(A).
Patients with RA (duration of at least 12 months) who were 
nonresponsive to MTX had 9.9% (DAS-28; NNT: 10) and 9.1% 
(ACR50; NNT: 11) increases in the clinical response rate after 
treatment with 500-1000 mg of abatacept every 30 days for 12 
months195(A).
Table 5 summarizes the ACR50 and DAS-28 measures, 
which are expressed as the estimated benefi ts with the NNT.
Recommendation
The various treatment regimens that use biologic DMARDs in 
combination with MTX in RA patients present similar results 
compared to MTX monotherapy, using ACR50 and DAS-28 as 
parameters with minor variations in the NNT (3–11 for ACR50 
and 4–10 for DAS-28). There are no direct comparisons that 
enable an accurate estimate of the differences in benefi ts be-
tween the various biologics.
Strategies for RA treatment in Brazil
DMARD treatment should be initiated immediately after di-
agnosis. The treatment should be adjusted as needed after 
frequent clinical evaluations within a period of 30–90 days.
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Treatment strategies based on specifi c goals produce bet-
ter clinical outcomes and functional capacities as well as low-
er structural radiographic damage, compared to conventional 
treatments94(A). The goal is remission or at least low disease 
activity; this outcome can be evaluated by composite indices 
of disease activity (CIDAs) while taking into consideration the 
role of treatment responses in reducing CIDA values, as estab-
lished in the 2011 Consensus of the SBR for the Diagnosis and 
Initial Assessment of Rheumatoid Arthritis5(D).
First line – synthetic drugs that alter the course of the disease 
MTX should be the fi rst choice for DMARD treatment95(A) 
66,200(D). In cases with contraindications, sulfasalazine201(A) 
or lefl unomide143(A) can be used as a fi rst option202(B). 
Antimalarial drugs (chloroquine diphosphate and 
hydroxychloroquine)203(B) might be indicated only for patients 
with mild disease or undifferentiated arthritis with low ero-
sion potential. In exceptional cases, such as patients with hy-
persensitivity to other DMARDs or those with viral hepatitis, 
gold sodium can be used.
MTX should preferentially be prescribed as a monotherapy 
during early treatment128(A).
In the absence of an objectifi ed clinical response (remis-
sion or lower disease activity) to the maximum tolerated 
MTX dose or in the presence of adverse events, it is recom-
mended that MTX be exchanged for another DMARD mono-
therapy or DMARD combinations. The most frequently used 
combinations are MTX with chloroquine, sulfasalazine, a 
combination of these three drugs15(A) and MTX combined 
with lefl unomide204(A). Therapy progression should be rapid, 
with monthly patient evaluations during the fi rst 6 months of 
treatment, and the doses and schedules should be adjusted 
as required. A maximum of six months should be allowed to 
defi ne an absence of response to the fi rst-line treatment66(D).
Low doses of corticosteroids (up to 15 mg/day of predni-
sone or equivalent) and anti-infl ammatories may be used at 
the beginning of the treatment regimen, although caution 
and usage for the shortest time possible are recommended to 
minimize the occurrence of adverse events66(D).
Second line – biologic disease-modifying drugs
Immunobiological RA treatment is indicated for patients who 
persist with moderate to high disease activity (according to 
CIDAs) despite treatment with at least two of the regimens 
proposed for the fi rst line of treatment. In Brazil, anti-TNF 
drugs are the fi rst choice of biologic therapy after the failure 
of synthetic DMARD regimens. This approach is justifi ed by 
the most comprehensive post-marketing experience, as well 
as the increased volume of safety information from clinical 
studies, registries and national205(B) and international66(D) 
recommendations. However, other drugs such as abatacept 
and tocilizumab may be prescribed at the discretion of the 
attending physician after a failure with synthetic DMARDs, 
given the publication of randomized controlled trials that 
support this indication40,88(A). Rituximab should be avoided as 
a fi rst-line biologic66(D) except in specifi c cases (e.g., patients 
with contraindications to other biologics, preferably those 
who are positive for RF and/or anti-CCP or those who present 
with a diagnosis associated with lymphoma).
In exceptional situations, biologic DMARDs may be indi-
cated after a failure of the fi rst regimen of synthetic DMARDs 
in patients with associated poor prognostic factors, including 
very high disease activity, a high number of painful/infl amed 
joints, high RF and/or anti-CCP levels and the early occur-
rence of radiographic erosions66(D). Poor prognosis factors are 
better detailed in the 2011 Consensus of the SBR Diagnosis 
and Initial Assessment of Rheumatoid Arthritis5(D).
The use of biologic drugs as a fi rst-line RA treatment is 
not indicated in Brazil because there is no evidence of cost-
effectiveness in this country.
Third line – failure or intolerance to modifying drugs in the 
course of biological disease
In clinical scenarios where there is no response to the initial 
biologic treatment, a progression to loss of response, or major 
adverse events, one biologic agent may be exchanged for an-
other. The biologics that have presented benefi ts in random-
ized clinical trials in patients for whom anti-TNF treatment 
failed are abatacept, rituximab and tocilizumab206(B). Patients 
for whom the fi rst anti-TNF agent failed have also derived 
benefi ts from the use of a second drug from the same class, 
including adalimumab, certolizumab, etanercept, golimumab 
or infl iximab, in prospective observational studies and ran-
domized controlled double-blind trials (golimumab), but un-
certainties persist about the magnitude of the therapeutic ef-
fects and the cost-effectiveness of this strategy207(B).
The choice of the employed treatment sequence remains 
at the discretion of the physician, depending on the particu-
larities of each case. A minimum of three months and a maxi-
mum of six months of clinical evaluation are recommended 
before proceeding to a change in regimen (switching between 
biologic DMARDs).
Withdrawal of medications and eventual suspension of therapy
There are no data that allow us to defi ne the RA treatment du-
ration, and currently the medication to which the patient has 
an adequate response should be maintained for an indefi nite 
period at the physician’s discretion. In cases of complete (re-
mission) and sustained (more than 6–12 months) responses, 
a gradual and careful withdrawal can be attempted according 
to the following sequence: fi rst NSAIDs, then corticosteroids 
Table 5 – ACR50 and DAS-28 measures expressed as the 
estimated benefi t using Number Needed to Treat (NNT).
Biologic Dose Time NNT
ACR50 DAS-28
Golimumab 50 mg 24 weeks 10 7
Adalimumab 40 mg 52 weeks 3 5
Etanercept 50 mg 52 weeks 5 5
Infl iximab 3 mg/kg 22 weeks 5 6
Certolizumab 200 mg 52 weeks 3 6
Rituximab 1,000 mg 52 weeks 6 5
Tocilizumab 8 mg/kg 24 weeks 3 4
Abatacept 500–1,000 mg 52 weeks 11 10
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and biologic DMARDs, while maintaining the use of synthetic 
DMARDs208(B). In exceptional situations, if remission is main-
tained, the physician may very cautiously attempt to with-
draw synthetic DMARDs66(D). Sustained drug-free remission 
is uncommon, especially in patients with biomarkers such as 
anti-CCP and/or RF.
Fig. 1 summarizes RA drug treatment in Brazil as a fl ow-
chart, as proposed by the RA SBR Commission.
Treatment monitoring
In patients with active early-stage disease and symptoms of a 
12-month duration or less, intensive monitoring with monthly 
visits is recommended with rapid medication progression when 
necessary209(B) 210(D). The treatment regimens and their possible 
adverse events have been discussed in previous sections.
At each visit, physicians should evaluate the effi cacy and 
safety of the therapeutic interventions while considering pa-
tient comorbidities and preferentially targeting remission or 
the lowest disease activity possible, as well as an improved 
functional status and quality of life. In patients with estab-
lished disease, especially in those with controlled disease, 
visits can occur every three months108,109,209(B) 210(D).
Table 6 summarizes in schematic form the monitoring fre-
quencies for the main parameters considered appropriate for 
evaluations of a patient undergoing RA treatment.
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174Table 6 – Monitoring the treatment of rheumatoid arthritis (continued). 
Parameter Initial assessment Monthly 
assessment 
(early RA)
Extra 
consultations
Assessment every 
three months 
(established RA)
Annual assessment
Education of patients and families X X X X X
CIDA+ X X X X X
mHAQ or HAQ-DI (0–3 points) X X X X
(minimum reduction desired: 0.22 
points)
RF/anti-CCP X X
(if negative at the fi rst assessment, 
they can be repeated in the two initial 
years)
Conventional radiography (hands and wrists, feet and ankles, 
other joints affected)
X X
Joint resonance or ultrasound (in doubt regarding the synovitis) X
Assessment of  extra-articular manifestations * X X X X X
Assessment of comorbidities** X X X X X
Infl ammatory activity tests (ESR and CRP) X X X X X
Laboratory assessment*** X X X X X
Vaccination assessment X X
Specifi c medicamentous treatment for RA**** X X X X X
Medicamentous treatment of comorbidities X X X X X
PPD (or IGRA) and chest radiography (if a biologic DMARD, 
specially anti-TNF, is prescribed)
X
Occupational therapy X X X X X
Rehabilitation X X X X X
Evaluation of orthotic indication X X X X X
Evaluation of surgical indication X X X X X
Coordination of the multidisciplinary team X X X X X
Gestational counseling X X X X X
Evaluation of infections (clinical assessment and occasional 
complementary exams)
X
Serologies (hepatitis B and 
hepatitis C at the beginning 
of the investigation, HIV in 
selected situations)
X X X X
Evaluation and education regarding emergency situations***** X X X X X
CIDA, compound indices of disease activity (SDAI – simple disease activity index; CDAI – clinical disease activity index; DAS28 – disease activity score - 28 joints); +, for CIDA goals, see the 2011 BSR 
Consensus for diagnosis and early assessment of RA; mHAQ, modifi ed health assessment questionnaire; HAQ-DI, health assessment questionnaire - disability index; ESR, erythrocyte sedimentation rate; 
CRP, C-reactive protein; PPD, tuberculin skin test; IGRA, interferon gamma release assays.
* Extra-articular manifestations: rheumatoid nodules, interstitial lung disease, serositis, ocular infl ammation, and vasculitides.
**Comorbidities: arterial hypertension, cardiovascular ischemia, diabetes mellitus, atherosclerosis, low bone mass, depression, fi bromyalgia, etc.
***Laboratory exams: blood count, liver function, lipid profi le, and renal function; depending on the comorbidities, consider additional exams.
****Medication for RA: consider the effi cacy and safety issues of each medication detailed throughout the text.
*****Urgencies on RA: scleromalacia perforans, myelopathies, multiple mononeuritis and vasculitis, pregnant patients on teratogenic drugs.
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